Willkie has extensive experience in the health care and life sciences field, both in the United States and abroad. We represent companies and investors in the areas of biotechnology, pharmaceuticals, medical technology, wellness and providers. Our work includes corporate transactions, mergers and acquisitions, joint venture transactions, compliance matters, IP issues, patent litigation and counseling, and general litigation.
Related Practice Areas
Experience
- Clovis Oncology, a developer and marketer of anti-cancer drugs, since its inception and in various acquisition-related transactions, principal licensing agreements and the following financings:
- $90 million public offering of common stock.
- $250 million 144A offering of convertible senior notes.
- $300 million underwritten public offering of convertible senior notes.
- $100 million underwritten public offering of common stock.
- $235.75 million underwritten public offering of common stock.
- $345 million underwritten public offering of common stock.
- $287.5 million 144A offering of convertible senior notes.
- $275 million underwritten public offering of common stock.
- ING Barings (Furman Selz) in a private placement of $10 million of Class C convertible preferred stock of Athersys, a clinical stage biopharmaceutical and genomics company.
- IPF Partners in a venture bond financing for French clinical stage biopharmaceutical company Adocia.
- Morgan Stanley Bank AG on the rights issue of German molecular diagnostics company Epigenomics, a developer and commercializer of proprietary products for the screening and diagnosis of cancer.
- Conducted an internal investigation on behalf of the Audit Committee of SeraCare.
- Aegerion Pharmaceuticals, Inc., a wholly owned subsidiary of Novelion Therapeutics, in its recapitalization, whereby Amryt Pharma Plc agreed to acquire 100% of Aegerion’s reorganized stock.
- Constellation Pharmaceuticals in connection with MorphoSys’s acquisition of Constellation Pharmaceuticals.
- eureKING, a European SPAC dedicated to bioproduction, in its business combination with Skyepharma.
- Morgan Stanley as financial advisor to Horizon Therapeutics in its $27.8 billion acquisition by Amgen.
- NextPharma on its agreement to acquire the Ploermel and Edinburgh production sites of biotechnology company Lonza.
- Qualium Investissement and Lauxera Capital Partners in their acquisition of a majority stake in VERDOT Ips².